DOCSLIB.ORG

Analytical Profiles of Drug Substances Volume 13

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

An a1y tic aI Profiles of Drug Substances Volume 13 EDITORIAL BOARD Abdullah A. Al-Badr Klaus Florey Steven A. Benezra Salvatore A. Fusari Rafik Bishara Lee T. Grady Gerald S. Brenner Boen T. Kho Glenn A. Brewer, Jr. Joseph A. Mollica Nicholas DeAngelis James W. Muiison John E. Fairbrother Milton D. Yudis Academic Press Rapid Manuscript Reproduction Analytical Profiles of Drug Substances Volume 13 Edited by Klaus Florey The Squilh Institute for Medical Research New Rriiiiswick, New Jersey Contrilmting Editors Abdullah A. Al-Badr Glenn A. Brewer, Jr. Norman W. Atwater Salvatore A. Fusari Steven A. Benezra Lee T. Grady Rafik Bishara James W. Munson Gerald S. Brenner Compiled tinder the auspices of tlw Pliuriiiaceutical Analysis (ind Control Section APhA Ac(idcmy of Plw t-titcrcentical Scimces ACADEMIC PRESS, INC. 1984 (Harcourt Brace Jovanovich, Publishers) Orlando San Diego New York London Toronto Montreal Sydney Tokyo COPYRIGHT 0 1984, BY THE AMERICANPHARMACEUTICAL ASSOCIATION ALL RIOHTS RESERVED. NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY INFORMATION STORAQE AND RETRIEVAL SYSTEM, WITHOUT PERMISSION IN WRITING FROM THE PUBLISHER. ACADEMIC PRESS, INC. Orlando, Florida 52887 United Kingdom Edition published by ACADEMIC PRESS, INC. LONDON) LTD. 24/28 Oval Road, London NWI 76X Library of Congress Cataloging in Publication Data Analytical profiles of drug substances. Compiled under the auspices of the Pharmaceutical Analysis and Control Section, Academy of Pharmaceutical Sciences. Includes bibliographical references and indexes. 1. Drugs--Analysis. I. Florey, Klaus. 11. Brewer, Glenn A. 111. Title: Academy of Pharmaceutical Sciences. Pharmaceutical Analysis and Control Section. [DNLM: 1. Drugs--Analysis--Yearbooks. QV740 AAl A551 RS189.A58 615l.1 70- 187259 ISBN 0-12-260813-5 (V. 13) PRINTED IN THE UNITED STATES OF AMERICA 84 85 86 81 9 8 7 6 5 4 3 2 1 CONTENTS Affiliations of Editors, Contributors, and Reviewers vii Preface ix Atenolo1 1 Vesna caplar, Zooniinira MokotiC-Milaun, Hrvoje Hofinan, Josip Kuftinec, Franjo KajfeZ, Antun Nagl, and Nikola BlaZeviC Camphor 27 Jaber S. Mossa and Muhoud M. A. Hassan Chloroy uine 95 Molaammad Tariq and Abdullalz A. Al-Badr Cimetidine 127 P. M. G. Bazjin, Alex Post, arid John E. Zarenibo Disopyramide Phosphate 183 Alan Wickinan and Patricia Finnegan Indomethacin 211 Matthew O’Brien, laines McCauley, and Edward Cohen Ketotifen 239 Zvonirnira MikotiC-Mihun, Josip Kuftinec, Hrcoje Hofman, Mladen ZiniC, Franjo Kajfei, and Zlatko MeiC Melphalan 265 L. Valentin Feyns Moxalactam Disodium 305 Leslie J. Lorenz and Patricici N. Thomas V vi CONTENTS Oxyphenbutazone 333 Abdullah A. Al-Badr and Hunieidn A. El-Obeid Pentazocine 36 1 Terry D. Wilson Yhen ytoin 417 Jose Philip, Ira J. Hokoinh, and Snhatare A. Fusnri Pyridoxine Hydrochloride 447 Hassun Y. Aboul-Eneiii and Mohaninied A. Lout$/ Saccharin 487 Muhammad Uppnl Zubnir and Mahinoud M. A. Hnssan Salicylamide 52 1 Salini A. Babhair, Abdullnh A. Al-Buds. and Hassan Y. Aboul-Enein Silver S ulfadiazine 553 Auke Bult and Cees h4. Plug Sulindac 573 Fotios M. Plakogiannis and James A. McCnuley Tetracycline Hydrochloride 597 Syed Laik Ali Vitamin D3 (Cholecalciferol) 655 K. Thonias Koshy and Willianc F. Beyer PROFILE SUPPLEMENTS Tolbu tamide 719 Said E. lbrahiin and Abdullah A. Al-Badr Reserpine 737 Farid j. Muhtadi ERRATUM Phenylpropanolamine Hydrochloride 767 Cumulative Index 769 AFFILIATIONS OF EDITORS, CONTRIBUTORS, AND REVIEWERS H. Y. Abod-Enein, King Saud University, Riyadh, Saudi Arabia A. A. Al-Badr, King Saud University, Riyadh, Saudi Arabia S, L. Ali, Zentrallaboratoriuin Deutscher Apotheker e. V., Eschborn, Federal Republic of Germany N. W. Atwater, E. R. Squibb & Sons, Princeton, New Jersey S. A. Babhair, King Saud University, Riyadh, Saudi Arabia P. M. G. Bauin, Smith Kline & French Research, Ltd., The Frythe, Welwy11, Hertfordshire, United Kingdom S. A. Benezm, Wellcoine Kesearch Laboratories, Research Triangle Park, North Carolina W. F. Beyer, The Upjohn Company, Kalamazoo, Michigan R. Bishara, Lilly Research Laboratories, Indianapolis, Indiana N. BlaZeuiC, Institute for the Control of Drugs, Zagreb, Yugoslavia G. S. Brenner, Merck Sharp & Dolime Research Laboratories, West Point, Pennsylvania G. A. Brewer, Jr.,The Squibl) Institute for Medical Research, New Bruns- wick, New Jersey A. Bult, State University of Leiden, Leiden, The NetherIands V. Cuplnr, Podravka-Institute, Zagreb, Yugoslavia E. Colzen, bferck Sharp & Dohme Rcscwdi Laboratories, West Point, Penn- sylvania N. DeAngelis, Wyeth Laboratories, Philadelphia, Pennsylvania H. A. El-Obeid, King Saud University, Riyadh, Saudi Arabia J. E. Fairbrother, Stiefel Lahratories Ltd., Sligo, Ireland L. V. Feyns, The United States Pharmacopeia, Rockville, Maryland P. M. Finnegan, G. D. Searle and Co., Skokie, Illinois K. Florey, The Squibb Institute for Medical Kesearch, New Brunswick, New Jersey vii ... Vlll AFFILIATIONS OF EDITORS, CONTRIBUTORS, AND REVIEWERS S. A. Fusari', Warner-Lambert Company, Morris Plains, New Jersey L. T. Grady, The United States Pharinacopeia, Rockville, Maryland M. M.A. Hnssan, King Sad University, Riyadh, Saudi Arabia H. Hofinan, Podravka-Institute, Zagreb, Yugoslavia I.J. Holcomb, Warner-Lambert Research Institute, Morris Plains, New Jersey S. E. Ibrahim, King Saud University, Riyadh, Saudi Arabia F . Kajfei , Podravka- Ins t it u tc , Zagreb , Yugoslavia B. T. Kho, Ayerst Laboratories, Rouses Point, New York K. Thomas Koshy, The Upjohn Company, Kalamazoo, Michigan J. Kuftinec, Podravka-Institute, Zagreb, Yugoslavia L. J. Lorens, Lilly Research Laboratories, Indianapolis, Indiana M. A. Loutfy, King Saud University, Kiyadh, Saudi Arabia J. A. McCauley, Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey Z. MeiC, Institute Ruder Boskovii., Zagreb, Yugoslavia Z. MikotiC-Mihun, Podravka-Institute, Zagreb, Yugoslavia J. A. Mollica, CIBA-GEIGY Corporation, Summit, New Jersev J. S. Mossa, King Saud University, Riyadh, Saudi Arabia F. J. Muhtadi, King Saud University, Riyadh, Saudi Arabia J. W. Munson, The Upjohn Company, Kalainazoo, Michigan A. Nagl, University of Zagreb, Zagreb, Yugoslavia M. O'Brien, Merck Sharp & Dohme Research Laboratories, West Point, Penn- sylvania J. Philip, Warner-Lambert Company, Morris Plains, New Jersey F. M. Plakogiannis, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Brooklyn, New York C. M. Plug, State University of Leiden, Leiden, The Netherlands A. Post, Smith Kline & French Laboratories, Philadelphia, Pennsylvania M. Tariq, King Saud University, Riyadh, Saudi Arabia P. N. Thomas, Lilly Research Laboratories, Indianapolis, Indiana A. Wickman, Searle Laboratories, Skokie, Illinois T. D. Wilson, Sterling-Winthrop Research Institute, Rensselaer, New York M. D.Yudis, Shering-Plough Inc., Bloomfield, New Jersey J. E. Zarembo', Smith Kline & French Laboratories, Philadelphia, Pennsyl- vania M. &nit, Podravka-Institute, Zagreb, Yugoslavia M. U. Zubair, King Saud University, Riyadh, Saudi Arabia 'Present address: 22625 St. Joan, St. Clair Shores, Michigan 48080. 'Present address: Revlon Health Care Group, Tuckahoe, New York 10707 PREFACE The compilation ofdnnlyticcil Profiles of Drug Szibstunces to supplement the information contained in the official compendia is now a well-established activity. That we are able to publish one voluine per year is a trilxite to the diligence of the editors to solicit articles and even more so to the enthusiastic re- sponse of our authors, an international group associated with pharmaceutical firms, academic institutions, and coinpendial authorities. I would like to ex- press my sincere gratitude to them for making this venture possible. Over the years, we have had queries concerning our publication policy. Our goal is to cover all drug sulxtaiices of medical valiie, and therefire, we have welcomed any papers of interest to an individual contributor. We also have endeavored to solicit profiles of the most useful and used medicines, hut inany in this category still need to be profiled. In the preface to the eleventh voliime, I announced that we would try to supplement previously published profiles with new data. Unfortunately, most of the original contributors are no longer available to undertake this task, and it has proven difficult to find other volunteers. We shall continue to pursue the updating program, but it will not be as comprehensive as originally envisioned. Again, I would like to request those who have found these profiles useful to contribute papers of their own. We, the editors, stand ready to receive such contributions. ix This Page Intentionally Left Blank ATENOLOL Vesna Caplar, ' Zvonimira Mikotid-Mihun, Hrvoje Hofman, Josip Kuftinec, Franjo Kajfei Podravka-I nstitute Zagreb, Yugoslavia Antun Nag1 IJnioerszt!l of Zagreb Zagreb, Yzigoslacia Nikola Blaievid lnstitiite for the Control of Drugs Zagreb, Ytigoslnoin 1. Foreword, History, Therapeutic Category 2 2. Description 2 2. I Name, Formula, Molecular Weight 2 2.2 Appearance, Color, Odor, Taste 2 3. Synthesis 2 4. Physical Properties 5 4.1 Spectra 5 4.2 Solid Properties 15 4.3 Solution Properties 19 5. Methods of Analysis 20 5.1 Elemental Analysis 20 5.2 Titrimetric Determination-Electrochemical 20 5.3 Chromatographic Methods 20 5.4 Determination of Impurities 22 6. Stability-Degradation 22 7. Drug Metabolism. Pharrnacokinetics, Bioavailability 22 8. Identification and Determination in Body Fluids and Tissues
Recommended publications
  • Prezentace Aplikace Powerpoint

    Prezentace Aplikace Powerpoint

    Analgesics - antipyretics = „weak“ analgesics = non-opioid analgesics Most of them also • non-steroidal anti-inflamatory drugs (NSAIDs) •antirheumatics Oldřich Farsa 2011 Metabolism of eicosanoids O O arachidonic O H acid = 2 C O R1 R2 OH R2 O OH CH C O P O + 3 H N CH 2 O 3 CH3 glucocorticoids inhibitors of phspholipase A2 prostaglandins sythesis = COOH = "weak" analgesics + lipoxygenase inhibitors + NSAIDs arachidonic acid cyclooxygenases (COX1 + COX2) lipoxygenase OOH O COOH COOH O PG 5-hydroperoxy-6-trans-8,11,14-cis-eikosatetraenoic acid G2 OOH (5-HPETE) cyklooxygenases tromboxan synthase prostacyklin synthase PG H2 PG I2 = prostacyklin TX A2 endothelium cells LT A4 trombocytes isomerases PG D2 PG E2 LT C4 LT B4 PG F2α all the cells LT D4 LT E4 Effects of prostaglandins ↓ Prostaglandin E, F2α : ache, fewer, inflammation, sekretion of HCl , stomach mucosa capilaries dilatation, contraction of + ↑ uterus, kidneys: excretion of Na and H2O Prostacyclin (prostaglandin I ): vasodilatation, platelets aggregation inhibition 2 Tromboxan: vasokonstriction, platelets aggregation activation Leukotriens: alergic reactions (e.g. asthma bronchiale) Cyklooxygenases (= prostaglandin G/H synthases) COX1 Constitutive: in all the tissues Functions: •protection of stomach mucosa (vasodilatation) •diuresis •platelets aggregation (TXA) COX2 Philipp Needlemann Constitutive: kidneys, brain (co-localized with cyclins D and E) inventor of COX 1 isoenzymes Inducible: macrophages, neutrophfils, fibroblasts, endothelium cells (1989) Functions: •vasodilatation
  • Networker Jukebox Control Command Nsrjb

    Networker Jukebox Control Command Nsrjb

    Maintenance Procedures NSRJB ( 8 ) NAME nsrjb − NetWorker jukebox control command SYNOPSIS nsrjb [ −C ][−j name ][−s server ][−v ][−f device ][−S slots | −T Ta gs | volume names ] nsrjb −L [ −j name ][−s server ][−gimnqvG ][−Y | −N ][−R | −B ][−b pool ][−f device | −J hostname ][−e forev er ][−c capacity ][−o mode ][−S slots | −T tags | volume names ] nsrjb −l [ −j name ][−s server ][−nvqrG ][−R [ −b pool ]][−f device | −J hostname ][−S slot | −T tags | volume names ] nsrjb −u [ −j name ][−s server ][−qv ][−f device ][−S slot | −T tags | volume names ] nsrjb −I [ −j name ][−s server ][−Evpq ][−I | −f device ][−S slots | −T tags | volume_names ] nsrjb −p [ −j name ][−s server ][−vq ][−f device ][−S slot | −T tag | volume name ] nsrjb −o mode [ −j name ][−s server ][−Y ][−S slots | −T tags | volume names ] nsrjb −H [ −j name ][−s server ][−EHvp ] nsrjb −h [ −j name ][−s server ][−v ] nsrjb −U uses [ −j name ][−s server ][−S slots | −T tags ] nsrjb −V [ −j name ][−s server ] nsrjb −d [ −j name ][−s server ][−v ][−N ][−Y ][−P ports ][−S slots ][−T tags ][volume names ] nsrjb −w [ −j name ][−s server ][−v ][−N ][−Y ][−P ports ][−S slots | −T tags | volume names ] nsrjb −a [ −j name ][−s server ][−vd ][−T tags |[−T tags ] volume names ] nsrjb −x [ −j name ][−s server ][−vwX ][−T tags | −S slots ] nsrjb −F [ −j name ][−s server ][−v ] −f device DESCRIPTION The nsrjb program manages resources in two broad classes of jukeboxes, remotely managed jukeboxes and locally managed jukeboxes. Remotely managed jukeboxes are controlled through an external agent.
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0156582 A1 Tsukamoto Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2009/0156582 A1 Tsukamoto Et Al

    US 20090156582A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0156582 A1 Tsukamoto et al. (43) Pub. Date: Jun. 18, 2009 (54) PYRAZOLE COMPOUND Publication Classification (76) Inventors: Tetsuya Tsukamoto, Osaka-shi, (51) Int. Cl. Osaka (JP); Takeshi Yamamoto, A6II 3/55 (2006.01) Osaka-shi,Osaka (JP); Ryosuke A63L/454 (2006.01) Tokunoh, Osaka-shi, Osaka (JP); A63L/462 (2006.01) Tomohiro Kawamoto, Osaka-shi, C07D 403/02 (2006.01) Osaka (JP); Masahiro Okura, Osaka-shi, Osaka (JP); Masakumi (52) U.S. Cl. .................... 514/217.09: 514/406; 514/326; Kori, Osaka-shi, Osaka (JP); 548/364.1: 548/368.4: 546/211; 540/603 Katsuhito Murase, Osaka-shi, Osaka (JP) (57) ABSTRACT Correspondence Address: The present invention provides a pyrazole compound repre WENDEROTH, LIND & PONACK, L.L.P. sented by the formula (I): 1030 15th Street, N.W., Suite 400 East Washington, DC 20005-1503 (US) b (Io) (21) Appl. No.: 11/884,054 Ra R (22) PCT Filed: Feb. 9, 2006 (86). PCT No.: PCT/UP2006/302686 S371 (c)(1), wherein ring Ao is a pyrazole ring optionally further having 1 (2), (4) Date: Sep. 14, 2007 or 2 substituents; R is a substituted carbamoyl group; and R' (30) Foreign Application Priority Data is an optionally Substituted acylamino group, or a salt thereof or a prodrug thereof, which is useful as an agent for the Feb. 9, 2005 (JP) .................................. O333562005 prophylaxis or treatment of GSK-3? related pathology or Dec. 22, 2005 (JP) .................................. 3709622005 disease, and a GSK-3? inhibitor including same. US 2009/0156582 A1 Jun.
  • Sleason, Redwood City, CA (US), Juan W. W333. a 3. C

    Sleason, Redwood City, CA (US), Juan W. W333. a 3. C

    USOO8288373B2 (12) United States Patent (10) Patent No.: US 8,288,373 B2 Chen et al. (45) Date of Patent: Oct. 16, 2012 (54) MODULATORS OF CXCR7 FOREIGN PATENT DOCUMENTS AU 2006-230674 A1 11, 2006 (75) Inventors: Xi Chen, Palo Alto, CA (US); Pingchen WO WOO2,08221 A2 1, 2002 Fan, Fremont, CA (US); Mark M. WO WOO3,O764OO A1 9, 2003 Sleason, Redwood City, CA (US), Juan W. W333. A 3. C. Jaen, Burlingame, CA (US). Lianfa WO WO 2007/126935 A2 11/2007 Li, Palo Alto, CA (US); Jeffrey P. WO WO 2008/008518 A1 1/2008 McMahon, Mountain View, CA (US); WO 2008, 11215.6 A1 9, 2008 Jay Powers, Pacifica, CA (US); Yibin Zeng, Foster City, CA (US); Penglie OTHER PUBLICATIONS Zhang, Foster City, CA (US) Konishi et al. (Yakugaku Zasshi (1973), 93(5), 684-7). Abstract.* r Miao et al., “CXCR7 (RDC1) promotes breast and lung tumor growth (73) Assignee: Chemocentryx, Inc., Mountain View, in vivo and is expressed on tumor-associated vasculature.” 2007. CA (US) PNAS, vol. 104. No. 40, pp. 15735-15740. c Zabel et al., “Elucidation of CXCR-7-Mediated Signaling Events and (*) Notice: Subject to any disclaimer the term of this Inhibition of CXCR4-Mediated Tumor Cell Transendothelial Migra patent is extended or adjusted under 35 tion by CXCR7 Ligands.” The Journal of Immunology, 2009, vol. U.S.C. 154(b) by 171 days. 183, Issue 5, pp. 3204-3211. International Search Reportmailed on Jan. 27, 2010, for International (21) Appl. No.: 12/612,638 Application No. PCT/US09/63298 filed on Nov.
  • Molecular Rearrangements in the Camphor Series : the Decomposition Products of the Methyl Ester of Isoaminocamphonanic Acid

    Molecular Rearrangements in the Camphor Series : the Decomposition Products of the Methyl Ester of Isoaminocamphonanic Acid

    MOLECULAR REARRANGEMENTS IN THE CAMPHOR SERIES. THE DECOMPOSITION PRODUCTS OF THE METHYL ESTER OF ISOAMINOCAMPHONANIC ACID. BY GLENN SEYMOUR SKINNER A. B. Kansas State Manual Training Normal, 1913 A. M. University of Illinois, 1915 THESIS Submitted in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY IN CHEMISTRY IN THE GRADUATE SCHOOL OF THE UNIVERSITY OF ILLINOIS 1917 Digitized by the Internet Archive in 2013 http://archive.org/details/molecularrearranOOskin SK3 UNIVERSITY OF ILLINOIS THE GRADUATE SCHOOL .191 7 I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPER- VISION BY .QleiirL...S.eymo.nr.....S.]s;i.nner ENTITLED .MQlficulax....E.earrii.ng_meiits in... the .G.amj2hgr....Se^^^^ The I)ejG.QiQ.p.Q.ai.t.i.o.rL...I!r.Q.d.iL.c.t.s Q±....tha.JvIe.l]i3fl....B.st.e..r o.t.....Is..oanDn.ocam^^^^^ Acid. BE ACCEPTED AS FULFILLING THIS PART OF THE REQUIREMENTS FOR THE DEGREE OF.. .J).Q.C..1i.QX._..Q±....PJlilQ.S..Q.p.llZ. In ChargeCI of Thesis Head of Department Recommendation concurred in :* .<:. TSr:^. Committee on Final Examination* *Required for doctor's degree but not for master's. •^L^n .X o o TABLE OF GONTEIITS. PART I. HISTORICAL. The Camphors ------------------------- 1 The Camphoric Acids --------------------- 2 The Methyl Esters of d-Camphoric and 1-Isocaraphoric Acid - - - 3 The Methyl Esters of d-Camphoramidic and l-Isocamphoramidic Acids 4 The d-Oamphoramidic and 1- Is o camphoramidic Acids ------- 6 The Amino Acids Which are Derived from the d-Gamphoramidic and 1-Isocamphoramidic Acids ---------- 7 The Methyl Esters of the Amino Acid-S - -- -- -- -- -- -- 8 The Decomposition Products of Amino Camphonanic Acid ----- 8 The Decomposition Products of Dihydroaminocampholytic Acid - - 10 The Decomposition of Isoaminocamphonanic Acid ----- - 15 The Decomposition of Isodihydr oaminocampholytic Acid ----- 15 The Unsaturated Acids- -------------------- 1^ The Hydroxy Acids- ---------------------- 1^ The Hydrocarbons ----------------------- 22 The Lactones ------------------------- PART II.
  • Etats Rapides

    Etats Rapides

    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
  • Command Control Interface Command Reference

    Command Control Interface Command Reference

    Command Control Interface Command Reference Hitachi Virtual Storage Platform G1000 Hitachi Unified Storage VM Hitachi Virtual Storage Platform Hitachi Universal Storage Platform V/VM FASTFIND LINKS Contents Product Version Getting Help MK-90RD7009-19 © 2010-2014 Hitachi, Ltd. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying and recording, or stored in a database or retrieval system for any purpose without the express written permission of Hitachi, Ltd. Hitachi, Ltd., reserves the right to make changes to this document at any time without notice and assumes no responsibility for its use. This document contains the most current information available at the time of publication. When new or revised information becomes available, this entire document will be updated and distributed to all registered users. Some of the features described in this document might not be currently available. Refer to the most recent product announcement for information about feature and product availability, or contact Hitachi Data Systems Corporation at https://portal.hds.com. Notice: Hitachi, Ltd., products and services can be ordered only under the terms and conditions of the applicable Hitachi Data Systems Corporation agreements. The use of Hitachi, Ltd., products is governed by the terms of your agreements with Hitachi Data Systems Corporation. Notice on Export Controls. The technical data and technology inherent in this Document may be subject to U.S. export control laws, including the U.S. Export Administration Act and its associated regulations, and may be subject to export or import regulations in other countries.
  • Gasket Chemical Services Guide

    Gasket Chemical Services Guide

    Gasket Chemical Services Guide Revision: GSG-100 6490 Rev.(AA) • The information contained herein is general in nature and recommendations are valid only for Victaulic compounds. • Gasket compatibility is dependent upon a number of factors. Suitability for a particular application must be determined by a competent individual familiar with system-specific conditions. • Victaulic offers no warranties, expressed or implied, of a product in any application. Contact your Victaulic sales representative to ensure the best gasket is selected for a particular service. Failure to follow these instructions could cause system failure, resulting in serious personal injury and property damage. Rating Code Key 1 Most Applications 2 Limited Applications 3 Restricted Applications (Nitrile) (EPDM) Grade E (Silicone) GRADE L GRADE T GRADE A GRADE V GRADE O GRADE M (Neoprene) GRADE M2 --- Insufficient Data (White Nitrile) GRADE CHP-2 (Epichlorohydrin) (Fluoroelastomer) (Fluoroelastomer) (Halogenated Butyl) (Hydrogenated Nitrile) Chemical GRADE ST / H Abietic Acid --- --- --- --- --- --- --- --- --- --- Acetaldehyde 2 3 3 3 3 --- --- 2 --- 3 Acetamide 1 1 1 1 2 --- --- 2 --- 3 Acetanilide 1 3 3 3 1 --- --- 2 --- 3 Acetic Acid, 30% 1 2 2 2 1 --- 2 1 2 3 Acetic Acid, 5% 1 2 2 2 1 --- 2 1 1 3 Acetic Acid, Glacial 1 3 3 3 3 --- 3 2 3 3 Acetic Acid, Hot, High Pressure 3 3 3 3 3 --- 3 3 3 3 Acetic Anhydride 2 3 3 3 2 --- 3 3 --- 3 Acetoacetic Acid 1 3 3 3 1 --- --- 2 --- 3 Acetone 1 3 3 3 3 --- 3 3 3 3 Acetone Cyanohydrin 1 3 3 3 1 --- --- 2 --- 3 Acetonitrile 1 3 3 3 1 --- --- --- --- 3 Acetophenetidine 3 2 2 2 3 --- --- --- --- 1 Acetophenone 1 3 3 3 3 --- 3 3 --- 3 Acetotoluidide 3 2 2 2 3 --- --- --- --- 1 Acetyl Acetone 1 3 3 3 3 --- 3 3 --- 3 The data and recommendations presented are based upon the best information available resulting from a combination of Victaulic's field experience, laboratory testing and recommendations supplied by prime producers of basic copolymer materials.
  • U.S. EPA, Pesticide Product Label, COMMAND 4E HERBICIDE, 09/02

    U.S. EPA, Pesticide Product Label, COMMAND 4E HERBICIDE, 09/02

    Don carlson, Ph.D. FMC corporation Agricultural Chemical Group 1735 Market street Philadelphia, PA 1910 3 Dear Dr. Carlson: Subject: Camand 4 EC Herbi,lde EPA Reg. No. 279-30~1 RE: Amended Labeling (tillage/nQ-tillage directions) Your Submission Dated August 13, 1992 ~he labeling refprred to above, submitted in connection with registration under the Federal Insecticide, Fungicide, and Rodenticide Act, as amended, is acceptable. A stamped copy is enclosed for your records. Sincerely yours, Robert J. Taylor Product I'anager (25) Fungicide-Herbicide Branch Registration Division (H7505C) CONCURRENCES SYMBOL;: l/7.)~.$P" ............... ... .................. ................. ................. ................................................... ::N£AM~, '%f:1; .... ........................................................................................................................ OFFICIAL FILE COPY _ i2 a a all a an a. .a $A 4SQS4 4t P ) ) Code 1139 Net Contents Command®4 E Herbicide For Agricultural or Commercial Use Only NOT FOR SALE OR USE IN CAUFORNIA EPA Reg. No. 279-3071 EPA Est. 279- Active Ingredient: By Wt. Clomazone: 2-(2-Chlorophenyl)methyl-4. 4-dimethyl-3-isoxazolidinone •...........••••..... 44.4% Inert Ingredients: .........•..............•......... 55.6% 100.0% Contains 4 pounds 01 active ingredient per gallon U.S. Patent No. 4.405,357 KEEP OUT OF REACH OF CHILDREN CAUTION FIRST AID " In SyH: Flush with plenty 0/ water. Get medical attention as AtlL.C OF CONTENTS 'Ossible. ' aI inlormations an pages 1-4 belore referring 10 specific ; swallowed: Drink prompUy large quatltities 01 crop use. alcohol. Do nol ind~'C8 vomiting. cau a physician, " Inh8led: Remove to fresh air. " Page lion. prelerably mouth·to-mouth.·. possible. ~~.::::::::::::::::::::::::::::::::::::::::::::: 1 Precautionary Statements ............................ ... 1 " on akin: Wash Skin Diredions lor Use ....................................... 1 allention. ~ and ~ ...............•.......•.......•... 2 For Emergency f!prayer CIeanuo ......................................
  • Antagonists of Il-6 to Prevent Or Treat

    Antagonists of Il-6 to Prevent Or Treat

    (19) TZZ ¥_ _T (11) EP 2 376 126 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 39/00 (2006.01) C07K 16/24 (2006.01) 20.12.2017 Bulletin 2017/51 (86) International application number: (21) Application number: 09830695.4 PCT/US2009/006266 (22) Date of filing: 24.11.2009 (87) International publication number: WO 2010/065077 (10.06.2010 Gazette 2010/23) (54) ANTAGONISTS OF IL-6 TO PREVENT OR TREAT THROMBOSIS ANTAGONISTEN VON IL-6 ZUR PRÄVENTION ODER BEHANDLUNG VON THROMBOSE ANTAGONISTES D IL-6 POUR PRÉVENIR OU TRAITER LA THROMBOSE (84) Designated Contracting States: • MATSUYAMA MASASHI ET AL: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR "Anti-interleukin-6 receptor antibody HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL (tocilizumab) treatment of multicentric PT RO SE SI SK SM TR Castleman’s disease", INTERNAL MEDICINE, JAPANESE SOCIETY OF INTERNAL MEDICINE, (30) Priority: 05.02.2009 US 366567 TOKYO, JP; BIOSCIENCES INFORMATION 14.07.2009 US 502581 SERVICE, PHILADELPHIA, PA, US, vol. 46, 1 25.11.2008 US 117811 P January 2007 (2007-01-01), pages 771-774, 25.11.2008 US 117861 P XP002696891, ISSN: 0918-2918, DOI: 24.02.2009 US 391717 10.2169/INTERNALMEDICINE.46.6262 06.03.2009 US 399156 • EMILLE D ET AL: "ADMINISTRATION OF AN 25.11.2008 US 117839 P ANTI-INTERLEUKIN-6 MONOCLONAL 24.02.2009 US 391615 ANTIBODY TO PATIENTS WITH ACQUIRED IMUNODEFICIENCY SYNDROME AND (43) Date of publication of application: LYMPHOMA: EFFECT ON LYMPHOMA GROWTH 19.10.2011 Bulletin 2011/42 AND ON B CLINICAL SYMPTOMS", BLOOD, AMERICAN SOCIETY OFHEMATOLOGY, US, vol.
  • Weed Control Guide for Ohio, Indiana and Illinois

    Weed Control Guide for Ohio, Indiana and Illinois

    Pub# WS16 / Bulletin 789 / IL15 OHIO STATE UNIVERSITY EXTENSION Tables Table 1. Weed Response to “Burndown” Herbicides .............................................................................................19 Table 2. Application Intervals for Early Preplant Herbicides ............................................................................... 20 Table 3. Weed Response to Preplant/Preemergence Herbicides in Corn—Grasses ....................................30 WEED Table 4. Weed Response to Preplant/Preemergence Herbicides in Corn—Broadleaf Weeds ....................31 Table 5. Weed Response to Postemergence Herbicides in Corn—Grasses ...................................................32 Table 6. Weed Response to Postemergence Herbicides in Corn—Broadleaf Weeds ..................................33 2015 CONTROL Table 7. Grazing and Forage (Silage, Hay, etc.) Intervals for Herbicide-Treated Corn ................................. 66 OHIO, INDIANA Table 8. Rainfast Intervals, Spray Additives, and Maximum Crop Size for Postemergence Corn Herbicides .........................................................................................................................................................68 AND ILLINOIS Table 9. Herbicides Labeled for Use on Field Corn, Seed Corn, Popcorn, and Sweet Corn ..................... 69 GUIDE Table 10. Herbicide and Soil Insecticide Use Precautions ......................................................................................71 Table 11. Weed Response to Herbicides in Popcorn and Sweet Corn—Grasses
  • Cheatsheet V2.4.Pdf

    Cheatsheet V2.4.Pdf

    ! ! 2.4!Edition! Cross!reference!processes!with!various!lists:! Scan!a!block!of!code!in!process!or!kernel!memory! psxview! for!imported!APIs:! ! impscan!! Show!processes!in!parent/child!tree:! !!!!Hp/HHpid=PID!!!!!!!!!Process!ID!! pstree! !!!!Hb/HHbase=BASE!!!Base!address!to!scan! & !!!!Hs/HHsize=SIZE!!!!!!!Size!to!scan!from!start!of!base! Process&Information& ! ! Logs&/&Histories& Specify!–o/HHoffset=OFFSET!or!Hp/HHpid=1,2,3!! ! ! Recover!event!logs!(XP/2003):! Display!DLLs:! evtlogs!! ! ! dlllist! !!!!HS/HHsaveHevt!!!!!!!!!!!!!!!!!!!!Save!raw!event!logs! Development!build!and!wiki:! ! !!!!HD/HHdumpHdir=PATH!!!Write!to!this!directory! github.com/volatilityfoundation!! Show!command!line!arguments:! ! ! cmdline! Recover!command!history:! Download!a!stable!release:! ! cmdscan!and!consoles!! volatilityfoundation.org!! Display!details!on!VAD!allocations:! ! ! vadinfo![HHaddr]! Recover!IE!cache/Internet!history:! Read!the!book:! ! iehistory!! artofmemoryforensics.com! Dump!allocations!to!individual!files:! ! ! vaddump!HHdumpHdir=PATH![HHbase]! Show!running!services:! Development!Team!Blog:! ! svcscan!! http://volatilityHlabs.blogspot.com!! Dump!all!valid!pages!to!a!single!file:! !!!!Hv/HHverbose!!!!Show!ServiceDll!from!registry! ! memdump!HHdumpHdir=PATH! ! (Official)!Training!Contact:! ! Networking&Information& Display!open!handles:! [email protected]!! ! handles!! ! Active!info!(XP/2003):! !!!!Ht/HHobjectHtype=TYPE!!!Mutant,!File,!Key,!etc…! Follow:!@volatility! connections!and!sockets!! !!!!Hs/HHsilent!!!!!!!!!!!!!!!!!!!!!!!!!!!Hide!unnamed!handles!